Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

A multicenter, randomized, investigator-masked, parallel-group trial compar ed bimatoprost and latanoprost for efficacy and safety in patients with gla ucoma or ocular hypertension. Patients received bimatoprost 0.03% (n = 119) or latanoprost 0.005% (n = 113) once daily in the evening for 3 months. Vi sits were at prestudy, baseline (day 0), week 1, and months 1, 2, and 3. Pr imary outcome measures were mean IOP and the percentage of patients achievi ng IOP of 17 mm Hg or lower at 8:00 AM. Secondary outcome measures were diu rnal IOP measurements (8:00 AM, 12 noon, 4:00 PM, 8:00 PM) at month 3 and S afety measures including adverse events. Mean IOP was lower with bimatopros t than with latanoprost at all time points during the 3-month follow-up, al though the between-group difference was not always statistically significan t. At month 3 at 12 noon, mean IOP was as much as 1.0 mm Hg lower with bima toprost (P = .021). Target pressures of less than or equal to 17 mm Hg were reached more often with bimatoprost than with latanoprost at 8:00 AM (53% vs 43%; P = .029). Over all diurnal measurements at month 3, low target pre ssures of less than or equal to 13, less than or equal to 14, and less than or equal to 15 mm Hg were achieved significantly more often with bimatopro st (P less than or equal to .006). Both drugs were safe and well tolerated. Conjunctival hyperemia was more common with bimatoprost, while headache wa s more frequent with latanoprost. Bimatoprost provided lower mean pressures than latanoprost at every time point throughout the study and was statisti cally superior in achieving low target pressures. More patients reached low target pressures with bimatoprost.